An implanted shunt diverts CSF from the ventricles within the brain or the subarachnoid spaces around the brain and spinal cord to another body region where it will be absorbed. This creates an alternative route for removal of CSF which is constantly produced within the brain and usually restores the physiological balance between CSF production, flow, and absorption when one or more of these functions has been impaired. Valves contained within the shunt pathway act like on-off switches, opening when the differential pressure (DP) – i.e., the pressure difference across the valve – exceeds the valve’s opening pressure. Valves are either set to a fixed pressure or they can be adjustable from outside the body. Accessory devices may be added to the shunt to modify valve function.
This report contains market size and forecasts of Ventriculoperitoneal (VP) Shunt in global, including the following market information:
Global Ventriculoperitoneal (VP) Shunt Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Ventriculoperitoneal (VP) Shunt Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Ventriculoperitoneal (VP) Shunt companies in 2021 (%)
The global Ventriculoperitoneal (VP) Shunt market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Fixed Pressure Valves Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Ventriculoperitoneal (VP) Shunt include Sophysa, Aesculap, B. Braun Melsungen, Integra lifesciences and Medtronic, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ventriculoperitoneal (VP) Shunt manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ventriculoperitoneal (VP) Shunt Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ventriculoperitoneal (VP) Shunt Market Segment Percentages, by Type, 2021 (%)
Fixed Pressure Valves
Variable Pressure Valves
Global Ventriculoperitoneal (VP) Shunt Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ventriculoperitoneal (VP) Shunt Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics and Ambulatory Care centers
Laboratories
Others
Global Ventriculoperitoneal (VP) Shunt Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ventriculoperitoneal (VP) Shunt Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ventriculoperitoneal (VP) Shunt revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Ventriculoperitoneal (VP) Shunt revenues share in global market, 2021 (%)
Key companies Ventriculoperitoneal (VP) Shunt sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Ventriculoperitoneal (VP) Shunt sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sophysa
Aesculap
B. Braun Melsungen
Integra lifesciences
Medtronic